Mr. Jacobs is Managing Director of Jacobs Investment Company, LLC. In addition, Mr. Jacobs serves on the boards of Next Generation Technologies and Fallbrook Technologies and is Chairman of Nutrina, Ltd., a biotechnology company focused on bioactive supplements for infant formulas. Mr. Jacobs is also actively involved with education and philanthropy, serving as Chairman of the Board of Trustees of High Tech High in San Diego and Chair of the Dean’s Advisory Council for Social Sciences at the University of California, San Diego. Mr. Jacobs received his bachelor’s degree in management science from the University of California, San Diego.
Scott R. Pancoast
Mr. Pancoast has served as the President and Chief Executive Officer of Lpath since March 2005 and as a Director of Lpath since 1998. Prior to joining Lpath, from 1994 to 2005, Mr. Pancoast was the Executive Vice President of Western States Investment Corporation (WSIC), a private San Diego venture capital fund. He has served as the CEO or interim CEO for six start-up companies, and has been a member of the boards of directors for over 15 companies, including two public companies. Mr. Pancoast previously served on the board of directors of iVOW, Inc., a publicly traded company. From 1986 to 1994, Mr. Pancoast was with National Sanitary Supply Company, where he was a member of the Board of Directors and served in various management positions, including Senior Vice President—Operations and Chief Financial Officer. He is a graduate of the Harvard Business School and the University of Virginia. Mr. Pancoast’s qualifications to sit on our Board include his experience as a venture capitalist and business leader, his current and past service as a DermTech board member, and his current and past service as a board member for public and private companies.
Mr. Posard brings over 30 years experience of general management and commercialization experience in the biotechnology and diagnostics industry. His expertise is introducing novel and transformational products to medical and research markets while scaling organizations efficiently. Mr. Posard has held executive title responsibilities with several highly successful growth companies including Illumina, Biosite and Gen-Probe. From 2006 to 2015, he held executive positions at Illumina as its VP of Marketing, VP Global Sales and then as Senior VP, General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units. Mr. Posard currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Talis Biomedical, Ignite Bio, and Stemson Therapeutics. He holds a bachelor’s degree in management science from UC San Diego.
Herm Rosenman brings more than 30 years of public company operating and financial experience. Mr. Rosenman has served as a member of the board of directors of Natera, Inc. since 2017, and as its CFO from 2014 to 2017. Prior to that, he was the SVP of finance and CFO of Gen-Probe Inc., where he was instrumental in its 2002 IPO and its 2012 sale to Hologic Inc. Prior to joining Gen-Probe, Mr. Rosenman was president and CEO of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, and president and CEO of RadNet Management Inc., a large healthcare provider. From 2012 to 2014, Mr. Rosenman focused on his board memberships. He has served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, since 2013, and of Vivus, Inc., a biopharmaceutical company, also since 2013. Mr. Rosenman also previously served on the board of directors of BioFire Diagnostics, Medistem, Inc., a stem cell therapy company, ARYx Therapeutics Inc., a private drug discovery and development company, Infinity Pharmaceuticals, Inc., a drug discovery and development company, and several privately held companies. Mr. Rosenman holds a BBA in accounting and finance from Pace University and an MBA in finance from the Wharton School of the University of Pennsylvania.
Gene Salkind, M.D.
Dr. Salkind has practiced neurosurgery in the Philadelphia area for approximately 25 years. He has also held professorships at leading teaching hospitals including the University of Pennsylvania Medical School and the Albert Einstein Medical Center. He has published multiple papers and been a guest lecturer at congresses worldwide. Dr Salkind is Trustee Emeritus of Temple University School of Medicine. He received his B.A. from the University of Pennsylvania (cum laude) and his M.D. from the Temple University School of Medicine.
Cynthia (Cindy) Collins most recently served as CEO of Human Longevity Inc. Prior to HLI, she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics. Ms. Collins previously served as President and CEO of GenVec, a publicly-traded therapeutics company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter. Earlier, Ms. Collins served as President and CEO of Sequoia Pharmaceuticals, Inc., and President of Clinical Micro Sensors, Inc. Ms. Collins received her bachelor’s degree in microbiology from the University of Illinois, Urbana and her MBA, from The University of Chicago Booth School of Business.
John Dobak, M.D.
President and CEO
John Dobak, M.D., has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD.